Incidence of CXCR4 tropism and CCR5-tropic resistance in treatment-experienced participants receiving maraviroc in the 48-week MOTIVATE 1 and 2 trials

Lignende værker

• Assessment of Maraviroc Exposure–Response Relationship at 48 Weeks in Treatment-Experienced HIV-1–Infected Patients in the MOTIVATE Studies
  af: Jacqmin, P, et al.
  Udgivet: (2013)
• A population pharmacokinetic meta-analysis of maraviroc in healthy volunteers and asymptomatic HIV-infected subjects
  af: Chan, Phylinda L S, et al.
  Udgivet: (2008)
• Emergence of CXCR4-Using Human Immunodeficiency Virus Type 1 (HIV-1) Variants in a Minority of HIV-1-Infected Patients following Treatment with the CCR5 Antagonist Maraviroc Is from a Pretreatment CXCR4-Using Virus Reservoir
  af: Westby, Mike, et al.
  Udgivet: (2006)
• Maraviroc – A CCR5 Antagonist for the Treatment of HIV-1 Infection
  af: Van Der Ryst, Elna
  Udgivet: (2015)
• Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1
  af: Giaquinto, Carlo, et al.
  Udgivet: (2018)